Parsec Financial Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | $246K | Hold |
2,673
| – | – | 0.01% | 269 |
|
|
2022
Q4 | $242K | Buy |
+2,673
| New | +$225K | 0.01% | 270 |
|
|
2021
Q3 | – | Sell |
-2,518
| Closed | -$230K | – | 284 |
|
|
2021
Q2 | $230K | Buy |
2,518
+24
| +1% | +$2.14K | 0.01% | 250 |
|
|
2021
Q1 | $213K | Hold |
2,494
| – | – | 0.01% | 251 |
|
|
2020
Q4 | $236K | Buy |
2,494
+188
| +8% | +$16.4K | 0.01% | 234 |
|
|
2020
Q3 | $201K | Sell |
2,306
-100
| -4% | -$8.66K | 0.01% | 231 |
|
|
2020
Q2 | $210K | Buy |
+2,406
| New | +$208K | 0.01% | 225 |
|
|
2020
Q1 | – | Sell |
-2,828
| Closed | -$268K | – | 253 |
|
|
2019
Q4 | $268K | Buy |
2,828
+162
| +6% | +$14.5K | 0.02% | 217 |
|
|
2019
Q3 | $232K | Sell |
2,666
-284
| -10% | -$25.5K | 0.01% | 219 |
|
|
2019
Q2 | $269K | Sell |
2,950
-1,000
| -25% | -$84.6K | 0.02% | 206 |
|
|
2019
Q1 | $340K | Sell |
3,950
-669
| -14% | -$53.7K | 0.02% | 194 |
|
|
2018
Q4 | $355K | Buy |
4,619
+27
| +0.6% | +$2.1K | 0.03% | 190 |
|
|
2018
Q3 | $355K | Buy |
4,592
+180
| +4% | +$13.3K | 0.02% | 194 |
|
|
2018
Q2 | $299K | Sell |
4,412
-367
| -8% | -$25.3K | 0.02% | 197 |
|
|
2018
Q1 | $346K | Sell |
4,779
-53
| -1% | -$4.04K | 0.02% | 195 |
|
|
2017
Q4 | $364K | Sell |
4,832
-828
| -15% | -$62.5K | 0.02% | 195 |
|
|
2017
Q3 | $435K | Hold |
5,660
| – | – | 0.03% | 192 |
|
|
2017
Q2 | $423K | Buy |
5,660
+173
| +3% | +$12.3K | 0.03% | 154 |
|
|
2017
Q1 | $365K | Hold |
5,487
| – | – | 0.03% | 157 |
|
|
2016
Q4 | $358K | Buy |
5,487
+261
| +5% | +$16.9K | 0.03% | 160 |
|
|
2016
Q3 | $370K | Buy |
5,226
+90
| +2% | +$6.56K | 0.03% | 158 |
|
|
2016
Q2 | $380K | Hold |
5,136
| – | – | 0.04% | 147 |
|
|
2016
Q1 | $333K | Sell |
5,136
-865
| -14% | -$58.8K | 0.03% | 151 |
|
|
2015
Q4 | $463K | Buy |
6,001
+770
| +15% | +$61.2K | 0.05% | 135 |
|
|
2015
Q3 | $431K | Hold |
5,231
| – | – | 0.05% | 134 |
|
|
2015
Q2 | $461K | Buy |
5,231
+335
| +7% | +$30.7K | 0.05% | 129 |
|
|
2015
Q1 | $433K | Buy |
4,896
+864
| +21% | +$76.6K | 0.04% | 135 |
|
|
2014
Q4 | $335K | Hold |
4,032
| – | – | 0.04% | 134 |
|
|
2014
Q3 | $340K | Buy |
4,032
+111
| +3% | +$8.98K | 0.04% | 131 |
|
|
2014
Q2 | $318K | Sell |
3,921
-669
| -15% | -$52.6K | 0.03% | 131 |
|
|
2014
Q1 | $350K | Buy |
4,590
+1,125
| +32% | +$82K | 0.04% | 123 |
|
|
2013
Q4 | $250K | Sell |
3,465
-129
| -4% | -$8.97K | 0.03% | 132 |
|
|
2013
Q3 | $247K | Hold |
3,594
| – | – | 0.03% | 122 |
|
|
2013
Q2 | $228K | Buy |
+3,594
| New | +$234K | 0.03% | 123 |
|
Other funds holding NVS
Parsec Financial Management's NVS Position: Q1 2023 in Review
Parsec Financial Management held its Novartis (NVS) position steady in Q1 2023 at 2,673 shares worth $246K. The position accounts for 0.01% of the portfolio, ranked #269.
Parsec Financial Management first reported a position in NVS in Q2 2013 and has held it in 34 quarters since. The position peaked at $463K in Q4 2015. 1,180 funds tracked by Wall St. Rank hold NVS as of Q1 2023.
- Parsec Financial Management held 2,673 shares of Novartis worth $246K as of Q1 2023.
- Parsec Financial Management left its Novartis share count unchanged in Q1 2023.
- Novartis made up 0.01% of Parsec Financial Management's portfolio in Q1 2023, its #269 holding.
- Parsec Financial Management first reported a position in Novartis in Q2 2013 and has held it in 34 quarters since.
- Parsec Financial Management's Novartis position peaked at $463K in Q4 2015.
- 1,180 funds tracked by Wall St. Rank held Novartis as of Q1 2023.
Based on Parsec Financial Management's 13F filing for Q1 2023, filed 6 Apr 2023.